Rapid responses are electronic letters to the editor. They enable our users to debate issues raised in articles published on thebmj.com. Although a selection of rapid responses will be included online and in print as readers' letters, their first appearance online means that they are published articles. If you need the url (web address) of an individual response, perhaps for citation purposes, simply click on the response headline and copy the url from the browser window. Letters are indexed in PubMed.
I recently proposed that the enzyme 'Tubulin Tyrosine Ligase' (TTL)
may supress tumors by enhancing tubulin nitrotyrosination, leading to
microtubule dysfunction and therefore cell death (Idriss, HT. Nitric
Oxide, 4:1-3). Many tumor cells seem to have suprressed levels of TTL and
therefore may escape tubulin nitrotyrosination-mediated cytotoxicity. I
was wondering if gene therapy of TTL could ultimately lead to tumor
shrinkage, perhaps when complemented with Tumor Necrosis Factor (TNF)